News & Updates
Filter by Specialty:

Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021
Fatty acid synthase (FASN) is commonly expressed in operable triple-negative breast cancer (TNBC) and is associated with a poor prognosis, but omeprazole can hamper FASN activity, which may potentially boost the efficacy of neoadjuvant chemotherapy, according to the results of a phase II study.
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021
Quadruple therapy with empagliflozin/dapagliflozin affords long-term glycaemic control
08 Nov 2021
byJairia Dela Cruz
A four-drug combination that includes either empagliflozin or dapagliflozin helps keep glucose in check through 3 years for patients with type 2 diabetes (T2D), in addition to its positive effect on weight and tolerable safety profile, as shown in an open-label randomized controlled study.